MK&A

We help pharma build mutually beneficial partnerships with influencers and groups from patient & professional communities. #PatientEngagement

[MK&A @mkaglobal]

We're excited to announce our new name! MK&A is now VOZ Advisors. Voz means voice, which is central to our mission: giving voice to multiple stakeholders throughout all stages of drug discovery/commercialization. Please follow us on our new handle @vozadvisors!

[MK&A @mkaglobal]

LAST CHANCE TO REGISTER! Oct 2nd webinar: "Can ERNs become pharma's platform of choice for real world evidence?" Explore overlapping challenges & opportunities in collecting clinical data for registries, clinical trials, & European Reference Networks! https://t.co/ZgGTKlUAaL

[MK&A @mkaglobal]

Join Ellen Coleman at the @DrugInfoAssn #Patient18 conference where she will
be serving on the Program Committee. We're looking forward to it!
https://t.co/FxljV8iaba

[MK&A @mkaglobal]

WEBINAR OCT 2—"Can ERNs become pharma's platform of choice for real world evidence?" Mark Krueger joins in exploring overlapping challenges & opportunities in collecting clinical data for registries, clinical trials, & European Reference Networks. REGISTER https://t.co/ZgGTKlUAaL

[MK&A @mkaglobal]

Read Ellen Coleman's, @mkaglobal's President and CEO, latest article published in the June feature of @PM360online where she highlights the benefits of advocacy relations for legacy brands. #strategy #advocacyrelations
https://t.co/UCRBE2nCt3

[MK&A @mkaglobal]

MK&A President, Ellen Coleman, will lead a forum and discuss how healthcare providers have historically collaborated sharing patient insights and developing a comprehensive program. #DIA2018

[MK&A @mkaglobal]

MK&A President, Ellen Coleman, will help lead a session today: Analyzing the outcomes of patient engagement that are important to stakeholders and what kind of measures can signal achievement. #DIA2018 #patientengagement

[MK&A @mkaglobal]

Ellen Coleman is interviewed in a recent podcast episode If Medicines Could Talk, covering #PatientAdvocacy and market access: importance of compliance, engaging early & combined leadership to measure return on engagement for both company and patients.

https://t.co/LzN0GHlCDs

[MK&A @mkaglobal]

MK&A founder Mark Krueger takes on a new role today as chief strategic officer, focusing on providing high-level counsel to clients, advancing thought leadership on key trends and topics impacting the biopharma industry and expanding the firm.

[MK&A @mkaglobal]

Congratulations to Ellen Coleman on her promotion to MK&A president & CEO. Ellen builds on her years of strong leadership and excellent work at MK&A to assume responsibility for the operation and direction of the firm.

[MK&A @mkaglobal]

Meet @ClaudiaHirawat, biopharma industry veteran and new owner and executive chair of MK&A. Cláudia brings 23 years of experience, extensive knowledge of the biopharma industry and a fervent dedication to #patientadvocacy to MK&A.

[MK&A @mkaglobal]

MK&A has been acquired by Cláudia Hirawat, former president of PTC Therapeutics, MK&A client, and member of the firm’s board of advisors. Founder Mark Krueger remains as chief strategic officer, and Ellen Coleman is promoted to president and CEO. https://t.co/m0CjSyl6MO

[MK&A @mkaglobal]

Global Rare Disease Diagnosis & Care Access: Are we there yet? https://t.co/RgYGYXt6yu via #constantcontact

[MK&A @mkaglobal]

On Friday, The Washington Post published a new Kaiser Health study story, https://t.co/bBvnM6iAHC MK&A President Mark Krueger responds, suggesting three ways of confronting this challenge https://t.co/0DwKAJhnzo

[MK&A @mkaglobal]

Webinar Recording Available: Patient Advocacy-Missing Ingredient to Market Access Success https://t.co/KgoWLOv6BD

[MK&A @mkaglobal]

We are LIVE! MK&A's free webinar: Driving Market Access Through Patient Advocacy: Trends, Challenges and Opportunities, brings together US and EU industry experts to share their insights. To hear from the panelists and join the conversation click here: https://t.co/qcZddh8JHV

[MK&A @mkaglobal]

Carol Meyer just presented how @TakedaPharma is moving from developing medicines for patients to developing medicines with patients. Shifting to a culture of #PatientEngagement. #Patients2018

[MK&A @mkaglobal]

Here at #Patients2018 and looking forward to joining the conversation about how patients are involved in the #DrugDevelopmentLifeCycle

[MK&A @mkaglobal]

5 days left to register https://t.co/qcZddh8JHV for @mkaglobal webinar. Whether your access challenges are in the U.S., or Europe, or both, this event will cover it all, including the patient advocacy nuances in each market for accelerating your market access program.

[MK&A @mkaglobal]

Patient experience must be factored into value of emerging immuno-oncology therapies. @mkaglobal 's Tim Turnham @timturnham https://t.co/9eXpJZrwqh shares insights in current issue of MedAdNews (p. 27) https://t.co/ocGDMTRnbA